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accident’. Rather, a mechanism is
proposed that could activate
transcription of numerous genes in
spermatids. If a gene is transcribed
and its protein accumulates in
spermatids, it is very possible that
the protein will function there.
Regulation of holoenzyme levels
might also contribute to other cases
of cell-type-specific gene regulation.
Although no other cells seem to
accumulate as much of the basal
transcription machinery as early
spermatids do, overall transcription
rates do vary by more than an order of
magnitude between different somatic
tissue types [9]. Thus, differences in
levels of the basal transcription
machinery may be of wide-spread
importance in determining patterns
of cell-type-specific gene expression.
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Essay
Two hundred years of
vaccination
Derrick Baxby
In a world in which infectious
diseases seem once again to be on the
increase, it is perhaps fitting that 1996
sees various events to commemorate
the first documented smallpox
vaccination, performed by Edward
Jenner on May 14 1796 [1]. This
article will consider Jenner’s claim to
fame and a few of the key events in
the 200 years of vaccination that have
followed his pioneering experiment.
Jenner has always been a
controversial figure who polarized
opinion, with even his supporters
divided on whether he was a genius
or a simple country doctor. That he
preferred life in Gloucestershire
rather than London is certain.
Nevertheless, by 1796 he was a well-
respected doctor-scientist, trained in
London by John Hunter, with a
general practice in Berkeley and a
consultant practice in fashionable
Cheltenham [2]. 
Jenner the naturalist
Although Jenner’s name is
inextricably linked with vaccination
he should still have been
remembered, particularly by
zoologists, for his studies on bird
behaviour, even if he had not
developed smallpox vaccine. It had
long been known that the female
cuckoo lays her eggs in the nests of
other birds. It was not known,
however, how the eggs and nestlings
of the foster parents were disposed
of; the foster parents and the female
cuckoo were variously thought to be
responsible. In 1787, Jenner
observed that it was the newly
hatched cuckoo which ejected the
eggs and nestlings of its foster
parents; for this work he was made a
Fellow of the Royal Society (FRS)
in 1789 [2,3]. 
In these studies, Jenner was not
content just to report observations:
he tried to determine how and why
the observed events occurred. For
example, he described the
anatomical modification to the back
of the newly hatched cuckoo which
facilitates its murderous activities,
and which disappears within about
12 days of hatching. He also
reasoned that the adult cuckoo laid
its eggs in other birds’ nests because
it only stayed in Britain for about 11
weeks and would not have enough
time to rear its young before it
departed. At a time when some still
believed that birds hibernated, he
showed that the impulse to migrate
was connected with changes in the
reproductive organs and not due to
climate or availability of food. With
this analytical attitude it was perhaps
inevitable that Jenner would become
interested in the control of disease.
Jenner and smallpox
In the 18th century, smallpox was a
major killer, leaving visible scars on
many survivors. Its importance can
perhaps most easily be appreciated by
showing its effects on the family of
King Charles I (Fig. 1). Attempts had
been made for many years to control
smallpox by ‘variolation’, the
deliberate inoculation of smallpox
virus into the skin in the hope that a
mild but immunizing disease would
result. There was a risk of severe
smallpox for the inoculated and their
contacts, however. 
Jenner, an experienced variolator,
became interested in the current folk
lore concerning cowpox and smallpox
in the late 1770s. The idea was that
those individuals — traditionally
milkmaids — who had recovered
from cowpox could not later contract
smallpox. Cowpox was a mild
localized infection and Jenner
collected circumstantial information
that seemed to confirm the
milkmaids’ story. On May 14 1796,
just before his 47th birthday, he
inoculated 8 year-old James Phipps
at two sites with material taken from
the hand of a milkmaid, Sarah
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Nelmes (Fig. 2). The lesions
developed uneventfully and healed,
and six weeks later Phipps was
inoculated with smallpox, which had
no effect. Although probably not the
first to try this experiment, Jenner
was the first to report it. 
Jenner showed this information to
the Royal Society but was advised to
do more work, which he did in 1798
(see Fig. 3). The value of this small
trial was that it showed that the
material (soon to be called ‘vaccine’,
from the Latin vacca, a cow) could be
transmitted from a pustule on one
arm to another arm without altering
its effects, thus reducing reliance on
the cow as a source of material. He
published his results in his now
famous Inquiry of 1798 [4].
The number of people vaccinated
by Jenner was small and the duration
of immunity unknown. As a result,
Jenner caused some controversy with
the claim that his vaccine was safe and
induced lifelong immunity. Obviously,
more trials and long-term follow up
studies were needed to establish these
claims, and eventually the importance
of revaccination was recognized.
Although many influential
authorities saw the value of
vaccination and Jenner’s role in its
introduction, there was some
opposition to vaccination and/or
Jenner. Variolators saw the loss of a
lucrative monopoly. Others claimed
that their extended trials established
the value of vaccination, and
although there is some truth in this,
such work could only build on
Jenner’s foundations.
One very important feature of
Jenner’s work was the distinction he
drew between ‘true’ and ‘spurious’
cowpox. The former gave the
expected result: a mild localized
infection which produced immunity
to smallpox. Spurious cowpox
produced untoward effects and/or no
immunity and Jenner recognized
distinct varieties. In modern terms,
these would include other bovine
diseases infectious for humans, or
material from an old cowpox lesion
which no longer contained infective
virus and was contaminated with
pathogenic bacteria. Although the
excuse of spurious cowpox was used
to explain away genuine vaccine
failures and the need for
revaccination, Jenner’s ability to
grasp and explain this concept many
years before the provision of
laboratory facilities to support it was
remarkable.
Some early vaccines, particularly
those introduced by George Pearson,
and developed at the London
Smallpox Hospital, contained
smallpox virus due to initial
confusion over the appearance of
cowpox and inoculated smallpox.
Consequently, some claimed that
vaccine was simply modified
smallpox virus, and that Jenner had
introduced no new principle. If true,
this would severely damage Jenner’s
reputation — but vaccines were soon
introduced from cowpox in
circumstances where no
contamination could occur, and
modern studies have confirmed earlier
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Figure 1
Smallpox in the Royal House of Stuart.
Monarchs are indicated by crowns; green
boxes denote those who never had smallpox,
amber those who had smallpox but survived,
and red those killed by smallpox.
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Figure 2
Cowpox lesions on the hand of Sarah
Nelmes from which Jenner took material to
vaccinate James Phipps, May 14 1796.
views that smallpox vaccine could not
be derived from smallpox virus [2].
Jenner’s claim was initially based
on few vaccinations and he erred in
his belief that immunity was lifelong.
Nevertheless, his use of an animal
virus to induce immunity to smallpox
marks a distinct break with previous
practice. This, together with his
analysis of true and spurious cowpox,
without which vaccination could not
have been developed, justifies the
credit he has been given [1,2,5].
Vaccination against smallpox
became established world-wide —
though not without opposition — and
laid the foundation for the control
and eventual eradication of smallpox
[5]. Although vaccination reduced the
overall incidence of smallpox,
eradication was not achieved simply
by mass vaccination. A much more
active strategy was adopted: rewards
were offered and trained workers
sought out cases. Once detected,
cases and contacts were isolated until
they were no longer infectious. This
surveillance–containment strategy
effectively broke the chain of
transmission, often without the need
for mass vaccination, and proved the
key to eradication [5].
Into the modern era
The introduction of smallpox vaccine
was not immediately followed by the
development of other vaccines, for
simple but obvious reasons. Firstly,
by the 18th century, smallpox could
be diagnosed clinically, enabling
assessment of the effects of the
vaccine; the diagnosis of most other
infections was much less certain.
Secondly, until Pasteur and Koch
developed methods for the
cultivation of micro-organisms, only
clinical material could be used as
vaccine. Smallpox and cowpox were
ideal in this respect, but suitable
clinical material was not easily
available for other infections.
By 1881 Pasteur had developed
vaccines for anthrax and chicken
cholera. These were important
because they showed how micro-
organisms could be attenuated in
vitro, and that immunization could
be extended to other infections
including those in animals. Until
1881, vaccine and vaccination had
only one meaning, but Pasteur
proposed that, to honour Jenner, the
terms should include all
immunization procedures. In 1885,
Pasteur set two more important
precedents with his rabies vaccine: a
vaccine for both animals and
humans, and the use of a vaccine for
post-exposure prophylaxis.
Although typhoid vaccines
containing killed whole organisms
were used during the first world war,
their effectiveness was doubted and
the next major vaccine, for
tuberculosis, was developed by
Calmette and Guérin in 1921–1923.
Appropriately, their vaccine (BCG)
was developed from a bovine
tuberculosis strain. The importance of
anti-toxin immunity was appreciated
early in the 20th century, and by the
1920s toxoid vaccines (inactivated
toxin) were introduced for diphtheria
and tetanus. Effective virus vaccines
for such diseases as poliomyelitis,
measles, and rubella were developed
in the 1950s–1960s, based on the
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Figure 3
Jenner’s vaccinations described in his
Inquiry. Green highlights indicate accidental
infection; those highlighted in red resisted
subsequent variolation.
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important cell culture studies by
John Enders and colleagues [1,6].
Pioneer immunologists debated
the importance of cellular immunity,
as championed by Metchnikoff, and
humoral immunity, first expounded
by Nuttall and Flugge. At first, work
on toxin–antitoxin reactions indicated
that humoral immunity, involving
antigen–antibody reactions, was
particularly important. Subsequently
the importance of cell-mediated
immunity was appreciated, as was
the fact that different populations of
white blood cells are involved in the
two arms of the immune system. Cell-
mediated immunity is mediated via T
lymphocytes, whereas B lymphocytes
produce the antibodies involved in
humoral immunity. 
Concurrently, protein chemists
and immunologists investigated the
different classes of immunoglobulins,
in particular differences between
circulating antibodies (IgM and IgG)
and those secreted at mucosal surfaces
(IgA). Now it was possible to explain
the success and failures of vaccines,
and to predict vaccine requirements
for particular infections [1,7].
Modern vaccines
There are real or potential difficulties
with all vaccines. There may be
problems with attenuation of live
vaccines, with possible risks for
vaccinees or their contacts. With non-
infectious vaccines, there may be
problems in identifying and
preserving the immunogenic
components and of ensuring correct
presentation of the antigens so that
the appropriate immune response is
stimulated. With all vaccines, there
are potential problems of delivery
and storage, particularly in tropical
climates. In this respect, the WHO
Programme of Expanded
Immunization is building on
experience gained during the
Smallpox Eradication Campaign to
facilitate widespread use of vaccines.
There are still problems caused by, for
example, influenza virus, human
immunodeficiency virus (HIV), and
various respiratory and enteric
pathogens which have variable and/or
multiple serotypes, and also by
malaria, but progress is being made.
Various vaccines are being tested
against typhoid, cholera and rotavirus
gastroenteritis [1,8], and considerable
attention is being paid to a synthetic
subunit vaccine for malaria [9].
Various HIV vaccines are being
developed, and the recent isolation of
apparently naturally attenuated
mutants of HIV which lack the nef
gene suggests they may be developed
into attenuated vaccines [10].
Recombinant DNA technology
has already made a considerable
impact through the successful yeast
recombinant hepatitis B vaccine
[1,11], and it is appropriate that
smallpox vaccine still has a role to
play. Infectious vaccinia recombinant
vaccines which express the
immunogenic glycoprotein of rabies
virus are proving very successful in
Europe for oral immunization of
foxes, the principal wildlife reservoir
of rabies [12]. Although there are
reservations about the widespread use
of recombinant vaccinia vaccines,
particularly in humans, the technology
is being transferred to other
poxviruses. Candidate mammalian
vaccines are being developed using
recombinant canarypox vectors
which induce good immune
responses although they do not
replicate in mammalian cells [1,13].
Considerable interest is also
being shown in ‘DNA vaccines’ [14].
These comprise the appropriate gene
inserted into a plasmid carrier which,
when injected into the body, is taken
up by host cells. The viral gene is
expressed and the antigen
preferentially stimulates cell-
mediated immunity. By appropriate
use of reverse transcriptase,
recombinant DNA vaccines are
being developed for RNA virus
infections, particularly influenza.
Jenner’s pioneer work on
smallpox vaccine was not
immediately extended to the control
of other infections. However,
vaccines have made a significant
impact in developed countries,
through the control of, for example,
measles, diphtheria, tetanus and
polio, and the widespread use of these
and other vaccines in developing
countries should have similar effects.
There are still problems with
infectious diseases, however, and
current vaccine research may help to
solve these. Increasing concern about
antibiotic-resistant bacteria and the
slow rate of development of antiviral
drugs emphasizes the ‘truism’ that
prevention is better than cure; the
ultimate goal should be eradication.
This has been achieved for smallpox
[5], and is achievable for polio by the
year 2000 by mass vaccination [15].
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